Competition Commission of India rejects complaint against Franco-Indian Pharmaceuticals

By: | Published: February 9, 2017 10:34 PM

The Competition Commission has dismissed allegations of abuse of dominance against Franco-Indian Pharmaceuticals with respect to supply of medicines.

 

It was alleged that the opposite parties did not supply the ordered medicines to him due to non-production of no objection certificate (NOC) from the local chemist and druggist association. (Reuters)It was alleged that the opposite parties did not supply the ordered medicines to him due to non-production of no objection certificate (NOC) from the local chemist and druggist association. (Reuters)

The Competition Commission has dismissed allegations of abuse of dominance against Franco-Indian Pharmaceuticals with respect to supply of medicines. While rejecting the complaint, the regulator said there is no specific information available in the public domain to suggest that the company and its depot manager and clearing and forwarding agent could be dominant in any relevant market.

The informant was a registered wholesaler of medicines in Jaunpur, Uttar Pradesh.

It was alleged that the opposite parties did not supply the ordered medicines to him due to non-production of no objection certificate (NOC) from the local chemist and druggist association.

You May Also Want To Watch:

In a recent order, the Competition Commission of India (CCI) said the informant has not provided any “material to substantiate” his allegation that the opposite parties demanded an NOC.

“The Informant is regularly getting supplies of medicines from OP-1 (opposite party) (Franco-Indian Pharmaceuticals) indicating that it is not mandatory for him to produce NOC from the local chemist and druggist association for the same,” the regulator observed.

Get live Stock Prices from BSE and NSE and latest NAV, portfolio of Mutual Funds, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Switch to Hindi Edition